NewMoneyMoves
PerspectivesResearchTerminalsWeekend RWABoard
HomeEarningsEli Lilly and Company FY2024 Q3
Released
FY2024 Q3
Earnings Review
LLY
MISS

Eli Lilly and Company

Eli Lilly and Company · Biotech/Pharma (Obesity)

Wed, October 30, 2024·Before Market Open
BiotechLLYEarnings

01Wall Street Consensus

EPS$3.46
Revenue$12.2B

02Earnings Results

EPS$1.18-65.9%
Revenue$11.4B-6.6%

Key Checkpoints

    Upside Catalysts

      Risk Factors

        Detail

        EEPS History (Last 12 Quarters)

        Actual EPS vs Consensus — Green Beat · Red Miss

        Beat9
        Miss3
        Beat rate75%
        Detail

        SEPS 서프라이즈 히스토리

        Beat9Miss3Beat률 75%

        분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출

        컨센서스 대비 실제 EPS/매출 서프라이즈 (%)

        Comments

        Earnings
        Earnings Info
        SymbolLLY
        QuarterFY2024 Q3
        Report Date2024-10-30
        Report TimeBMO
        SectorBiotech/Pharma (Obesity)
        StatusReleased
        Wall Street Consensus
        EPS$3.46
        Revenue$12.2B
        Results
        Actual EPS$1.18
        Actual Revenue$11.4B
        NewMoneyMoves

        Global Investment through Themes

        Content

        ThemesIdeasReportsEarnings

        Explore

        GuideETFsPerspectivesTelegramNVIDIA PortfolioWeekly ReviewCredit & Leverage

        Community

        Daily News

        Legal

        Privacy PolicyTerms of ServiceDisclaimer

        © 2026 NewMoneyMoves. All rights reserved.